NYSE:AZN AstraZeneca (AZN) Stock Price, News & Analysis $175.34 -3.42 (-1.91%) Closing price 11/19/2026Extended Trading$176.12 +0.78 (+0.44%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AstraZeneca Stock (NYSE:AZN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AstraZeneca alerts:Sign Up Key Stats Today's Range$174.03▼$178.2950-Day Range$155.93▼$189.1852-Week Range$153.41▼$212.71Volume2.58 million shsAverage Volume2.92 million shsMarket Capitalization$271.94 billionP/E Ratio24.80Dividend Yield1.24%Price Target$206.67Consensus RatingModerate Buy Company Overview AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders. Among its well-known products are Tagrisso and Imfinzi in oncology; Farxiga for cardiovascular, kidney and metabolic conditions; Symbicort and Fasenra for respiratory diseases; and Soliris and Ultomiris for certain rare diseases. The company also develops vaccines and other biologic therapies through selected collaborations and research programs. AstraZeneca was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group. Its shares trade on the London Stock Exchange, and its American Depositary Receipts trade on the New York Stock Exchange under the symbol AZN. Pascal Soriot has served as the company’s chief executive officer since 2012. AI Generated. May Contain Errors. Read More AstraZeneca Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreAZN MarketRank™: 4.7936158503 of 5 starsAstraZeneca scored higher than 96% of companies evaluated by MarketBeat, and ranked 11th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingAstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.84, and is based on no strong buy ratings, 16 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialAstraZeneca has a consensus price target of $206.67, representing about 17.9% upside from its current price of $175.34.Amount of Analyst CoverageAstraZeneca has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AstraZeneca's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth10.96% Earnings GrowthEarnings for AstraZeneca are expected to grow by 10.96% in the coming year, from $10.22 to $11.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AstraZeneca is 24.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.99.Price to Earnings Ratio vs. SectorThe P/E ratio of AstraZeneca is 24.80, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.96.Price to Earnings Growth RatioAstraZeneca has a PEG Ratio of 1.39. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAstraZeneca has a P/B Ratio of 5.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.20% of the float of AstraZeneca has been sold short.Short Interest Ratio / Days to CoverAstraZeneca has a short interest ratio ("days to cover") of 0.93, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AstraZeneca has recently decreased by 7.65%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldAstraZeneca pays a meaningful dividend of 1.21%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAstraZeneca does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of AstraZeneca is 30.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, AstraZeneca will have a dividend payout ratio of 19.14% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.Read more about AstraZeneca's dividend. News and Social Media4.2 / 5News Sentiment0.64 News SentimentAstraZeneca has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 26 news articles for AstraZeneca this week, compared to 8 articles on an average week.Search Interest32 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 52% compared to the previous 30 days.MarketBeat Follows12 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AstraZeneca insiders have not sold or bought any company stock.Percentage Held by Institutions20.35% of the stock of AstraZeneca is held by institutions.Read more about AstraZeneca's insider trading history. Receive AZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AZN Stock News HeadlinesAstraZeneca slips Thursday, underperforms marketNovember 19 at 3:02 PM | marketwatch.comAstraZeneca (NYSE:AZN) Stock Price Breaks Below 200 Day Moving Average - Here's What HappenedNovember 19 at 3:40 AM | americanbankingnews.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 20 at 1:00 AM | American Alternative (Ad)AstraZeneca gets Jefferies backing as broker sees $80bn sales target within reachNovember 18 at 12:09 PM | proactiveinvestors.comThe Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV FinancialNovember 18 at 7:08 AM | finance.yahoo.comAstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?November 17 at 3:33 PM | finance.yahoo.comAstraZeneca fends off lawsuit over alleged Soliris drug monopolyNovember 16, 2026 | reuters.comAstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug KlygefaNovember 16, 2026 | finance.yahoo.comSee More Headlines AZN Stock Analysis - Frequently Asked Questions How have AZN shares performed this year? AstraZeneca's stock was trading at $183.14 at the beginning of the year. Since then, AZN stock has decreased by 4.3% and is now trading at $175.34. How were AstraZeneca's earnings last quarter? AstraZeneca Plc (NYSE:AZN) issued its earnings results on Saturday, October, 31st. The company reported $2.79 EPS for the quarter, topping analysts' consensus estimates of $2.60 by $0.19. The firm's quarterly revenue was up 6.5% on a year-over-year basis. Read the conference call transcript. When did AstraZeneca's stock split? AstraZeneca's stock reverse split before market open on Friday, January 30th 2026.The 1-2 reverse split was announced on Friday, January 30th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 30th 2026. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. Who are AstraZeneca's major shareholders? Top institutional shareholders of AstraZeneca include Fisher Asset Management LLC (0.74%), Rathbones Group PLC (0.52%), Sanders Capital LLC (0.45%) and M&G PLC (0.33%). View institutional ownership trends. How do I buy shares of AstraZeneca? Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AstraZeneca own? Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Pfizer (PFE), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Moderna (MRNA), Johnson & Johnson (JNJ) and Merck & Co., Inc. (MRK). Company Calendar Record date for 9/8 Dividend8/07/2026Ex-Dividend for 9/8 Dividend8/07/2026Dividend Payable9/08/2026Last Earnings10/31/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:AZN Previous SymbolNASDAQ:AZN CIK901832 Webastrazeneca.com Phone011 44 20 7304 5000Fax44-12-2335-2858Employees96,100Year Founded1999Price Target and Rating Average Price Target for AstraZeneca$206.67 High Price Target$216.00 Low Price Target$198.00 Potential Upside/Downside+17.9%Consensus RatingModerate Buy Rating Score (0-4)2.84 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)$7.07 Trailing P/E Ratio24.80 Forward P/E Ratio15.46 P/E Growth1.39Net Income$10.23 billion Net Margins17.68% Pretax Margin21.32% Return on Equity31.85% Return on Assets13.62% Debt Debt-to-Equity Ratio0.51 Current Ratio1.01 Quick Ratio0.79 Sales & Book Value Annual Sales$58.74 billion Price / Sales4.63 Cash Flow$12.68 per share Price / Cash Flow13.83 Book Value$33.41 per share Price / Book5.25Miscellaneous Outstanding Shares1,550,910,000Free FloatN/AMarket Cap$271.94 billion OptionableOptionable Beta0.24 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NYSE:AZN) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.